Streetbeat News

Regulatory

IPHA

Innate Pharma has received clearance from the US FDA for its IND application to start a Phase 1 clinical study of IPH4502, a Nectin-4 ADC, for solid tumors.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 6:47 am

AZN

Daiichi Sankyo and AstraZeneca's drug, datopotamab deruxtecan, did not achieve statistical significance in overall survival in a breast cancer trial, despite previous success in progression-free survival. The drug is being developed as a potential treatment option for metastatic breast cancer.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 6:42 am

AMZN

WMT

India's Competition Commission has intensified its antitrust investigation into Amazon and Walmart-backed Flipkart, requesting financial records to assess potential penalties. The investigation focuses on alleged anti-competitive practices, including preferential treatment and deep discounting.

Portfolio Pulse from Ananthu C U

September 23, 2024 | 6:26 am

BYDDY

TSLA

BYD, a Chinese electric vehicle manufacturer and Tesla rival, plans to establish its first South Asian assembly plant in Pakistan after being rejected by India. The plant, expected to be operational by 2026, is a collaboration with Pakistan's Hub Power. BYD aims to sell 100,000 electric cars annually in Pakistan by 2030, as part of its broader international expansion strategy.

Portfolio Pulse from Benzinga Neuro

September 23, 2024 | 3:22 am

SSNLF

TSM

TSMC and Samsung are exploring the construction of $100 billion chip megafactories in the UAE, driven by the AI boom and global expansion plans. These projects face technical and logistical challenges, including political concerns about AI chip shipments to China. The UAE aims to boost its domestic tech industry with these developments.

Portfolio Pulse from Benzinga Neuro

September 23, 2024 | 3:04 am

NVO

Senator Bernie Sanders criticized Novo Nordisk for the high price of its diabetes drug, Ozempic, in the U.S., highlighting that it can be sold for less than $100 but costs Americans nearly $1,000. Sanders attributes this to corporate greed and urges Novo Nordisk to lower prices.

Portfolio Pulse from Benzinga Neuro

September 23, 2024 | 2:19 am

BTCUSD

Kamala Harris, during a fundraiser at Wall Street, mentioned her support for innovative technologies like cryptocurrencies, marking a significant policy shift. This aligns her with other Democrats supporting digital innovation, potentially impacting the crypto market.

Portfolio Pulse from Aniket Verma

September 23, 2024 | 1:48 am

TSLA

Peter Schiff criticizes Trump's Mars landing promise, linking it to past economic issues. Elon Musk plans five SpaceX launches to Mars in two years, emphasizing private over government-led space exploration. Regulatory challenges for SpaceX are highlighted.

Portfolio Pulse from Benzinga Neuro

September 23, 2024 | 1:47 am

AAPL

Apple Inc. (NASDAQ:AAPL) faced mixed news this week, with lower-than-expected demand for iPhone 16 Pro models, strong sales reported by T-Mobile, EU regulatory scrutiny, and expansion plans in India. Analysts remain optimistic despite initial demand concerns.

Portfolio Pulse from Benzinga Neuro

September 22, 2024 | 4:19 pm

MSFT

NVDA

ORCL

The tech world is abuzz with AI developments, including Oracle's AI surveillance vision, Musk and Nvidia's AI personal assistants, LinkedIn's data misuse scrutiny, and Salesforce's critique of Microsoft's Copilot.

Portfolio Pulse from Benzinga Neuro

September 22, 2024 | 4:19 pm